Abstract
Background
This study evaluated the efficacy and safety of docetaxel, epirubicin, and 5-fluorouracil (5-FU) [DEF] as treatment for locally advanced unresectable or metastatic gastric cancer.
Methods
Thirty-seven patients participated in the study (median age, 56 years; range, 22–73 years); Eastern Cooperative Oncology Group performance status [PS], 0–2). Docetaxel 75 mg/m2 IV (day 1), 5-FU 500 mg/m2 IV (days 1–3), and epirubicin 50 mg/m2 IV (day 1) were administered every 3 weeks for six cycles.
Results
In total, 20/37 patients (54%) completed six treatment cycles. Thirteen patients (35%; 95% confidence intervals [CI], 20% to 51%) had an objective response; 1 patient (3%) achieved a complete response and 12 patients (32%) achieved partial responses. Stable disease was observed in 7 patients (19%) and progressive disease in 5 patients (14%). Twelve patients (32%) were unevaluable. Clinical benefit (based on PS, weight gain, and analgesic consumption) was observed in 11 patients (30%). Median follow-up was 41 months (range, 26–53 months), median time to progression was 6.6 months (range, 0.5–29.2 months), median overall survival was 10.7 months (range, 7.0–14.6 months), and 1-year survival was 40%. The regimen was well tolerated. Grade 3–4 febrile neutropenia occurred in 8 patients (22%; 6% of cycles) and grade 3–4 neutropenia in 1 patient (1% of cycles). The most frequent grade 3–4 toxicities were alopecia (11% of cycles), diarrhea (4% of cycles) and vomiting (2% of cycles); grade 1–2 asthenia and fatigue occurred in 43% of cycles.
Conclusion
DEF is effective in the treatment of advanced gastric cancer, and has a good safety profile.
Article PDF
Similar content being viewed by others
References
D Ho (1988) Epidemiologic studies in gastric cancer D Ho (Eds) Gastric cancer Churchill Livingstone New York, NY 1–25
Ministry of Health, Brazil. National Secretariat of Health Assistance. National Câncer Institute of Brazil. Cancer Control Program Coordination. — Pro-Onco. Estimates of Cancer: Incidence and Mortality in Brazil, 2002. Rio de Janeiro, Brasil. Available from: http://www.inca.gov.br/ (accessed May 14, 2004)
M Findlay D Cunningham (1993) ArticleTitleChemotherapy of carcinoma of the stomach Cancer Treat Rev 19 29–44 Occurrence Handle8431925 Occurrence Handle10.1016/0305-7372(93)90025-M Occurrence Handle1:STN:280:ByyC287jtlQ%3D
J Rubin JG Gallagher G Schroeder AJ Schutt RJ Dalton JW Kugler et al. (1996) ArticleTitlePhase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma Cancer 78 1888–91 Occurrence Handle8909307 Occurrence Handle10.1002/(SICI)1097-0142(19961101)78:9<1888::AID-CNCR7>3.0.CO;2-B Occurrence Handle1:CAS:528:DyaK28XmvFyltrc%3D
C Louvet A De Gramont B Demuynck B Nordlinger JE Maisani B Lagadec et al. (1991) ArticleTitleHigh-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer Ann Oncol 2 229–30 Occurrence Handle2043494 Occurrence Handle1:STN:280:By6B2MrgtFI%3D
AM Murad (1999) ArticleTitleChemotherapy for advanced gastric cancer: focus on new agents and combinations Cancer Control 6 361–8 Occurrence Handle10758568
NK Kim YS Park DS Heo C Suh SY Kim KC Park et al. (1993) ArticleTitleA phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813–18 Occurrence Handle8508349 Occurrence Handle1:STN:280:ByyB1cvkvFQ%3D
J Wils HO Klein DJ Wagener H Bleiberg H Reis F Korsten et al. (1991) ArticleTitleSequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer — a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group J Clin Oncol 9 827–31 Occurrence Handle2016625 Occurrence Handle1:STN:280:DyaK3M3gt1ajuw%3D%3D
G Cocconi M Bella S Zironi R Algeri F Di Costanzo V De Lisi et al. (1994) ArticleTitleFluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research J Clin Oncol 12 2687–93 Occurrence Handle7989945 Occurrence Handle1:STN:280:ByqD1c7otFU%3D
D Kelsen OT Atiq L Saltz D Niedzwiecki D Ginn D Chapman et al. (1992) ArticleTitleFAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer J Clin Oncol 10 541–8 Occurrence Handle1548519 Occurrence Handle1:STN:280:DyaK387ptl2lsw%3D%3D
U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem et al. (2000) ArticleTitleFinal results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648–57 Occurrence Handle10894863 Occurrence Handle1:CAS:528:DC%2BD3cXls12iurk%3D
A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe et al. (1997) ArticleTitleRandomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261–7 Occurrence Handle8996151 Occurrence Handle1:CAS:528:DyaK2sXnsV2msA%3D%3D
J Crown M O'Leary (2000) ArticleTitleThe taxanes: an update Lancet 355 1176–8 Occurrence Handle10791395 Occurrence Handle10.1016/S0140-6736(00)02074-2 Occurrence Handle1:CAS:528:DC%2BD3cXislegsrg%3D
JA Ajani DH Ilson K Daugherty R Pazdur PM Lynch DP Kelsen et al. (1994) ArticleTitleActivity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus J Natl Cancer Inst 86 1086–91 Occurrence Handle7912736 Occurrence Handle1:STN:280:ByuB1MzjsVQ%3D
JA Ajani J Fairweather P Dumas YZ Patt R Pazdur PF Mansfield (1998) ArticleTitleA phase II study of Taxol in patients with advanced gastric carcinoma Cancer J Sci Am 4 269–74 Occurrence Handle9689986 Occurrence Handle1:STN:280:DyaK1czlsVCnsg%3D%3D
A Ohtsu N Boku F Tamura K Muro Y Shimada K Saigenji et al. (1998) ArticleTitleAn early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer Am J Clin Oncol 21 416–9 Occurrence Handle9708646 Occurrence Handle10.1097/00000421-199808000-00021 Occurrence Handle1:STN:280:DyaK1cznt1emsw%3D%3D
A Sulkes J Smyth C Sessa LY Dirix JB Vermoken S Kaye et al. (1994) ArticleTitleDocetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group Br J Cancer 70 380–3 Occurrence Handle7914428 Occurrence Handle1:STN:280:ByuA3s7jtlU%3D
AI Einzig D Neuberg SC Remick DD Karp PJ O'Dwyer JA Stewart et al. (1996) ArticleTitlePhase II trial of docetaxel (Taxotere®) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Med Oncol 13 87–93 Occurrence Handle9013471 Occurrence Handle1:STN:280:ByiC28rntFQ%3D Occurrence Handle10.1007/BF02993858
D Mavroudis C Kourousis N Androulakis K Kalbakis S Agelaki S Kakolyris et al. (2000) ArticleTitleFrontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial Am J Clin Oncol 23 341–4 Occurrence Handle10955859 Occurrence Handle10.1097/00000421-200008000-00005 Occurrence Handle1:STN:280:DC%2BD3cvktFaquw%3D%3D
T Taguchi Y Sakata R Kanamaru M Kurihara M Suminaga J Ota et al. (1998) ArticleTitleLate phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A) (in Japanese) Jpn J Cancer Chemother 25 1915–24 Occurrence Handle1:STN:280:DyaK1M%2FhsVGnug%3D%3D
M Mai Y Sakata R Kanamaru M Kurihara M Suminaga J Ota et al. (1999) ArticleTitleA late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a Cooperative Study Group trial (group B) (in Japanese) Jpn J Cancer Chemother 26 487–96 Occurrence Handle1:STN:280:DyaK1M7pslyiug%3D%3D
YJ Bang WK Kang YK Kang HC Kim C Jackes E Zuber et al. (2002) ArticleTitleDocetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial Jpn J Clin Oncol 32 248–54 Occurrence Handle12324575 Occurrence Handle10.1093/jjco/hyf057
AM Murad A Petroianu RC Guimaraes BC Aragao LO Cabral AO Scalabrini-Neto (1999) ArticleTitlePhase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe and effective regimen Am J Clin Oncol 22 580–6 Occurrence Handle10597742 Occurrence Handle10.1097/00000421-199912000-00008 Occurrence Handle1:STN:280:DC%2BD3c%2FmsVKisA%3D%3D
E Kettner K Ridwelski U Keilholtz T Gallkowski H Gebauer K Kroning et al. (2001) ArticleTitleDocetaxel and cisplatin combination therapy for advanced gastric cancer: results of two phase II studies (abstract) Proc Am Soc Oncol 20 165
K Ridwelski T Gebauer J Fahlke H Kroning E Kettner F Meyer et al. (2001) ArticleTitleCombination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer Ann Oncol 12 47–51 Occurrence Handle11249048 Occurrence Handle10.1023/A:1008328501128 Occurrence Handle1:STN:280:DC%2BD3Mzit1OjtA%3D%3D
AD Roth R Maibach G Martinelli N Fazio MS Aapro O Pagani et al. (2000) ArticleTitleDocetaxel (Taxotere) — cisplatin (TC): an effective drug combination in gastric carcinoma Ann Oncol 11 301–66 Occurrence Handle10811496 Occurrence Handle10.1023/A:1008342013224 Occurrence Handle1:STN:280:DC%2BD3c3mvFKgsQ%3D%3D
JA Ajani M Fodor E Van Cutsem S Tjulandin V Moiseyenco A Cabral et al. (2000) ArticleTitleMultinational randomized phase II trial of docetaxel and cisplatin with or without 5-fluorouracil in patients with advanced gastric cancer or GE junction adenocarcinoma (abstract) Proc Am Soc Clin Oncol 19 247
S Cascinu F Graziano S Barni R Labianca G Comella R Casaretti et al. (2001) ArticleTitleA phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian Group for the Study of Digestive Tract Cancer Br J Cancer 84 470–4 Occurrence Handle11207039 Occurrence Handle10.1054/bjoc.2000.1631 Occurrence Handle1:CAS:528:DC%2BD3MXhvVartbk%3D
YH Kim SW Shin BS Kim JH Kim JG Kim YJ Mok et al. (1999) ArticleTitlePaclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric cancer Cancer 85 295–301 Occurrence Handle10023695 Occurrence Handle10.1002/(SICI)1097-0142(19990115)85:2<295::AID-CNCR5>3.0.CO;2-H Occurrence Handle1:CAS:528:DyaK1MXhtFGgt7w%3D
C Bokemeyer JT Hartmann CS Lampe MR Clemens D Quietzsch L Forkmann et al. (1997) ArticleTitlePaclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer Semin Oncol 24 S19-96–100
S Kohnoe M Yoshida I Takahashi Y Emi Y Maehara K Sugimachi et al. (1992) ArticleTitleEpirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells Anticancer Res 12 389–92 Occurrence Handle1580555 Occurrence Handle1:CAS:528:DyaK38XkvVaqu7Y%3D
CTC version 2.0. Cancer Therapy Evolution Program. Common Toxicity Criteria, version 2.0. DCTD, NCI, NIH and DHS, March 1998
World Health Organization (WHO). Handbook for reporting results of cancer treatment. Geneva: WHO Offset publication No. 48; 1979
JS Andersen HA Burris E Casper MR Green ML Rothemberg MR Modiano et al. (1994) ArticleTitleDevelopment of a new system for assessing clinical benefit for patients with advanced pancreatic cancer (abstract) Proc Am Soc Clin Oncol 13 461
P Laurén (1965) ArticleTitleThe two histological main types of gastric carcinoma: a diffuse and so-called intestinal type carcinoma Acta Pathol Microbiol Scand 64 31–49 Occurrence Handle14320675
S Cullinan C Moertel T Fleming JR Rubin JE Krook LK Everson et al. (1985) ArticleTitleA comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma JAMA 253 2061–7 Occurrence Handle2579257 Occurrence Handle10.1001/jama.253.14.2061 Occurrence Handle1:STN:280:DyaL2M7jsFalsw%3D%3D
F Honecker C Kollmannsberger D Quietzsch C Haag M Schroeder C Spott et al. (2002) ArticleTitlePhase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer Anticancer Drugs 13 497–503 Occurrence Handle12045461 Occurrence Handle10.1097/00001813-200206000-00008 Occurrence Handle1:CAS:528:DC%2BD38Xks12hsLY%3D
Roth AD, Maibach R, Falk S, Stupp R, Saletti P, Kaberle D, et al. Docetaxel–cisplatin–5FU (TCF) versus docetaxel–cisplatin (TC) versus epirubicin–cisplatin–5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 2004;23: abstract 4020. Updated data presented at the 2004 ASCO annual meeting (see www.ASCO.org for virtual meetings)
V Moiseyenko E Van Cutsem S Tjulandin Y Tchao S Sengupta E Zuber et al. (2002) ArticleTitleDocetaxel–cisplatin–5-FU (DCF) versus cisplatin–5–FU (CF) as first line therapy for gastric cancer: interim analysis results on efficacy and safety in a multicenter randomized phase III study (abstract) Proc Am Soc Clin Oncol 21 147a
Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, et al. Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003;22:249 abstract 999; and associated slide presentation (www.asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-002584,00.asp)
E Van Cutsem (2004) ArticleTitleThe treatment of advanced gastric cancer: new findings on the activity of the taxanes Oncologist 9 IssueIDSuppl 2 9–15 Occurrence Handle15161986 Occurrence Handle10.1634/theoncologist.9-suppl_2-9 Occurrence Handle1:CAS:528:DC%2BD2cXlsFOju7w%3D
RC Coombes CE Chilvers D Amadori F Medi G Fountzilas H Rauschecker et al. (1994) ArticleTitleRandomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study Ann Oncol 5 33–6 Occurrence Handle8172789 Occurrence Handle1:STN:280:ByuB38nptFY%3D
Author information
Authors and Affiliations
Consortia
Additional information
Presented at: 2002 ASCO Meeting (Poster Section): Proc Am Soc Clin Oncol 2002;21:163a and 2002 ESMO Meeting (Poster Section): Ann Oncol 2002;13(Suppl 5):192
Rights and permissions
About this article
Cite this article
Murad, A., Skare, N., Vinholes, J. et al. Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen. Gastric Cancer 9, 99–105 (2006). https://doi.org/10.1007/s10120-006-0361-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-006-0361-z